Paxlovid, which combines nirmatrelvir and ritonavir in one tablet, will require a prescription,
Mexican health regulator COFEPRIS said on Friday, January 15, 2022, it has approved US pharmaceutical company Pfizer’s antiviral oral treatment against COVID-19 for emergency use in adults at risk of mild or moderate complications .
Paxlovid, which combines nirmatrelvir and ritonavir in one tablet, will require a prescription, a statement said.
Pfizer has said the treatment was about 90% effective in preventing hospitalizations and deaths, and data suggested it maintains its effectiveness against the Omicron variant.
Late last year, COFEPRIS approved a similar treatment by Eli Lilly & Co.
,